Evidence map›Paper›PMID 40883867›Full record

ArticlePharmacoepidemiology and drug safety2025

Preregistration: A Key to Credible Real-World Evidence Generation.

Emma Simonsen, Shirley V Wang, Helene Kildegaard, Anton Pottegård

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Preregistration: A Key to Credible Real-World Evidence Generation.Pharmacoepidemiology and drug safety · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emma SimonsenClinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0002-0254-0479
Shirley V WangDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7761-7090
Helene KildegaardClinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
Anton PottegårdClinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0001-9314-5679

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreregistration of study protocols in a public repository promotes transparency and reproducibility in pharmacoepidemiological research. Despite its clear benefits, preregistration remains underutilized. PURPOSE: Here, we discuss the advantages of preregistration, explore barriers to its implementation, and highlight existing repositories for preregistering real-world evidence study protocols. A relatively new option is the Real-World Evidence Registry within the Open Science Framework (OSF), which we briefly introduce.

Indexed as

PharmacoepidemiologyRegistriesResearch DesignHumansReproducibility of Resultspreregistrationreal‐world datareal‐world evidencereproducibilitytransparency pharmacoepidemiology

Identifiers

PMID40883867
PMCPMC12397443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.